english.prescrire.org > Spotlight > 100 most recent > Finerenone (Kerendia°) in chronic kidney disease with albuminuria associated with type 2 diabetes

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Finerenone (Kerendia°) in chronic kidney disease with albuminuria associated with type 2 diabetes

 Marketing Authorisations   Patients with type 2 diabetes are at risk of microvascular disease, which can lead to kidney failure. The aldosterone receptor antagonist finerenone has been authorised in the European Union for use in patients with type 2 diabetes who have developed chronic kidney disease with albuminuria. Does finerenone reduce mortality or the incidence of end-stage kidney disease in this situation? And what are its adverse effects?
Full article available for download by subscribers (4 pages)

©Prescrire 1 October 2024

Source: "Finerenone (Kerendia°) in chronic kidney disease with albuminuria associated with type 2 diabetes" Prescrire Int 2024; 33 (263): 229-232. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter
 
 
See also:

"Dapagliflozin (Forxiga°)
in chronic kidney disease"
Prescrire Int 2022;